SummaryRMgm-5602
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene tagging |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 40127922 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Yanase R, Tewari R |
Name Group/Department | School of Life Sciences |
Name Institute | University of Nottingham |
City | Nottingham |
Country | UK |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-5602 |
Principal name | CDPK4-GFP |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Western blot analysis of schizont (for CDPK4 and SRPK1) and gametocyte (for MAP2 as MAP2 seems to be barely expressed in asexual blood stages) protein extracts, using an anti-GFP antibody, revealed major bands at 90 kDa for CDPK4-GFP, 183 kDa for SRPK1-GFP, 90 kDa for MAP2-GFP, and 29 kDa for unfused GFP (WT-GFP); the expected sizes for each. Each GFP-tagged PK was also observed by fluorescence in activated gametocytes. Live-cell fluorescence imaging of P. berghei asexual blood stages revealed a diffuse cytoplasmic distribution of CDPK4-GFP in both the schizonts and merozoites. In contrast SRPK1-GFP showed weak diffuse cytoplasmic expression with a strong focus at the location of the nuclear pole and towards the apex of the forming or mature merozoites. In contrast, no MAP2-GFP fluorescence was observed in asexual development. |
Gametocyte/Gamete | During male gametogenesis, CDPK4-GFP had a diffuse location in both cytoplasm and nucleus, along with a distinct focus in the cytoplasm six min post-activation. At the early stage of male gametogenesis (30 s to 6 min post activation), up to two foci of CDPK4-GFP were observed, whereas at the late stage (>6 min post activation, more than three foci were sometimes observed. SRPK1-GFP was located in the cytoplasm, concentrically surrounding the nucleus, MAP2-GFP had a nuclear location in activated male gametocytes. Because these PKs are essential for axoneme development and are located at distinct regions of the parasite cell (in particular the distinct CDPK4-GFP focus in male gametocytes), we examined their co-localisation with markers of MTOC biology, including chromosome segregation (kinetochore protein, NDC80) and basal body formation (cytoplasmic axonemal protein, kinesin-8B, which were C-terminally tagged with mCherry (mCh). No co-localisation was observed between CDPK4-GFP, SRPK1-GFP or MAP2-GFP and NDC80-mCh during male gametogenesis, or between SRPK1-GFP and NDC80-mCh during schizogony, suggesting that these PKs do not directly interact with kinetochores during chromosome condensation. However, kinesin-8B-mCh appeared as a ring around SRPK1-GFP, suggesting that SRPK1 may be interacting with axoneme proteins or proteins involved in their assembly. CDPK4-GFP did not co-localise with kinesin-8B-mCh at any point. |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation To examine the spatiotemporal expression of the three protein kinases CDPK4 (PBANKA_0615200), SRPK1 (PBANKA_0401100) and MAP2 (PBANKA_0933700), transgenic P. berghei parasite lines were generated expressing the genes modified to code for a C-terminal GFP tag (RMgm-5602, RMgm-5603, RMgm-5604). An in-frame gfp coding sequence was inserted at the 3′ end of the endogenous gene locus using single crossover homologous recombination. Evidence is presented in the paper for the following: The mutant RMgm-5605 expresses a C-terminal GFP-tagged version of CDPK4 and an mCherry-tagged version of Kinesin-8b. The mutant has been obtained by crossing CDPK4-GFP (RMgm-5602) with Kinesin-8b::mCherry (RMgm-5324). Other mutants |
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0615200 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0717500 | ||||||||||||||||||||||||||
Gene product | calcium-dependent protein kinase 4 | ||||||||||||||||||||||||||
Gene product: Alternative name | CDPK4 | ||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Name of the tag | GFP | ||||||||||||||||||||||||||
Details of tagging | C-terminal | ||||||||||||||||||||||||||
Additional remarks: tagging | |||||||||||||||||||||||||||
Commercial source of tag-antibodies | |||||||||||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid single cross-over | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||||
Additional remarks genetic modification | To generate the GFP-tag lines, a region of each gene downstream of the ATG start codon was amplified, ligated to p277 vector, linearised using ClaI and transfected as described previously. The p277 vector contains the human dhfr cassette, conveying resistance to pyrimethamine. | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |